NFCR Writer Bradley Gillenwater, Author at NFCR

NFCR Writer Bradley Gillenwater

Faces & Voices of Cancer—In Depth: Alice-Anne Birch

“My story began in a tin-roofed farmhouse near the banks of the Tippecanoe River. My feisty, funny and brilliant maternal grandmother still ran one of the family farms, where they had returned during World War II. She was diagnosed with breast cancer my senior year in college, and my mother…...

Read more

Szent-Györgyi Prize Winner Profile Series: Dr. James Allison: The Main Act

“How wonderful that we have met with a paradox. Now we have some hope of making progress.” The words of acclaimed physicist Niels Bohr can be thought to apply to the somewhat counterintuitive notion that by engineering an element of the human body’s wondrous natural defense network to disengage, well-being…...

Read more

NFCR @ ASCO 2018

At least eight National Foundation for Cancer Research (NFCR) scientists will be on hand for the 54th annual meeting of the American Society of Clinical Oncology (ASCO), most prominently, Alice Shaw, M.D., Ph.D. They will join over 30,000 physicians, researchers, administrators and other professionals for the largest yearly gathering of…...

Read more

Two More Giants of Cancer Care® with NFCR Affiliation

Respected healthcare professionals who are advancing the field of oncology by their contributions in research and clinical practice were recognized this evening as Giants of Cancer Care in an event at the Adler Planetarium in Chicago. Two of the 21 honorees are recent fellows of the National Foundation for Cancer…...

Read more

An Evening Honoring Tremendous Achievement in Cancer Prevention

The National Foundation for Cancer Research’s (NFCR) annual marquee event was held in Washington, DC on Saturday evening, May 5th. The 2018 Szent-Györgyi Prize for Progress in Cancer Research ceremony and dinner occasioned much, including a gathering of NFCR principals and scientists, communication of the Foundation’s mandate, messages from the…...

Read more

Quartet of NFCR Scientists Publishes Papers in Immediate Succession

FOR IMMEDIATE RELEASE: May 16, 2018 CONTACT: National Foundation for Cancer Research Bradley Gillenwater, Senior Director for Global Programs & Communications E-mail: bgillenwater@nfcr.org / Phone: 301-961-9161 The Three Articles Offer Possible Bases for Brain Cancer Treatments, Insight into Somatic Mutations     ROCKVILLE, MD – A trio of papers co-authored by…...

Read more

NFCR at the 2018 American Association for Cancer Research Annual Meeting

The National Foundation for Cancer Research’s (NFCR) presence is considerable at the 109th annual meeting of the American Association for Cancer Research (AACR), which kicks off tomorrow in Chicago and runs through the following four days. One of the most widely anticipated regular gatherings of cancer scientists in the United…...

Read more

Global Collaborative Network Expands to Include Australia’s Eliminate Cancer Initiative

The National Foundation for Cancer Research (NFCR) today inked its second memorandum of understanding (MOU) within the past half year among major transnational cancer-fighting institutions. This pledge of cooperation follows on the heels of the formal commitment between the chairmen of itself and the China Pharmaceutical Innovation and Research Development…...

Read more

Safeway Foundation Grant Designated

The Safeway Foundation provided the National Foundation for Cancer Research (NFCR) a $50,000 grant to support innovative oncology research. The donation has been designated to NFCR Fellow Paul B. Fisher, M.Ph., Ph.D., at the Virginia Commonwealth University School of Medicine. The funds from The Safeway Foundation are being used to…...

Read more

NFCR Leads Delegation to Chinese BioMed Conference, Signs MOU with Host

The National Foundation for Cancer Research, led by Chairman Joseph F. Franlin and President Sujuan Ba, recruited a delegation of eight U.S. cancer technology start-ups for a successful exploratory mission to China. The companies—ArrayBio, Eutropics, Immix Biopharma, InterLeukin Therapeutics, International Cancer Impact Fund, InVaMet Therapeutics, Nonpareil Biotechnologies and Stromatis Pharma—were…...

Read more